Skip Navigation LinksHome > June 2012 - Volume 112 - Issue 6 > The First Drug for Treating Metastatic Basal Cell Carcinoma
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000415119.69358.0d
Drug Watch

The First Drug for Treating Metastatic Basal Cell Carcinoma

Aschenbrenner, Diane S. MS, RN

Collapse Box

Abstract

* Vismodegib (Erivedge) has been approved to treat locally advanced basal cell carcinoma and is the first drug approved to treat metastatic basal cell carcinoma.

* Vismodegib can cause severe birth defects, as well as the death of a fetus or embryo. Both men and women taking the drug must use effective contraception.

* The most common adverse effects are muscle spasms, alopecia, an altered or lost sense of taste, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, and vomiting.

© 2012 Lippincott Williams & Wilkins, Inc.

Login